Avanir Pharms Drug Patent Portfolio
Avanir Pharms owns 1 orange book drug protected by 3 US patents Given below is the list of Avanir Pharms's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7659282 | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders | 13 Aug, 2026 | Active |
| US8227484 | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders | 17 Jul, 2023 | Expired |
| USRE38115 | Dextromethorphan and an oxidase inhibitor for treating intractable conditions | 26 Jan, 2016 | Expired |
Latest Legal Activities on Avanir Pharms's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Avanir Pharms.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Maintenance Fee Reminder Mailed
Critical
| 11 Mar, 2024 | US8227484 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 28 Jul, 2021 | US7659282 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 09 Jan, 2020 | US8227484 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 16 Oct, 2014 | US8227484 |
|
Recordation of Patent Grant Mailed
Critical
| 24 Jul, 2012 | US8227484 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 24 Jul, 2012 | US8227484 |
|
Email Notification
Critical
| 05 Jul, 2012 | US8227484 |
|
Issue Notification Mailed
Critical
| 04 Jul, 2012 | US8227484 |
|
Email Notification
Critical
| 29 Jun, 2012 | US8227484 |
|
PG-Pub Issue Notification
Critical
| 28 Jun, 2012 | US8227484 |
| Dispatch to FDC | 23 Jun, 2012 | US8227484 |
|
Application Is Considered Ready for Issue
Critical
| 13 Jun, 2012 | US8227484 |
|
Electronic Review
Critical
| 11 Jun, 2012 | US8227484 |
| Mail Applicant Initiated Interview Summary | 11 Jun, 2012 | US8227484 |
|
Email Notification
Critical
| 11 Jun, 2012 | US8227484 |
Avanir Pharms's Family Patents
Avanir Pharms drugs have patent protection in a total of 22 countries. It's US patent count contributes only to 20.3% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click
below to unlock the full patent family tree.
Avanir Pharms Drug List
Given below is the complete list of Avanir Pharms's drugs and the patents protecting them.
1. Nuedexta
Nuedexta is protected by 3 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7659282 | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders |
13 Aug, 2026
(1 year, 9 months from now)
| Active |
| US8227484 | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders |
17 Jul, 2023
(1 year, 2 months ago)
| Expired |
| USRE38115 | Dextromethorphan and an oxidase inhibitor for treating intractable conditions |
26 Jan, 2016
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nuedexta's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List